GenPar Dipyridamole/Aspirin SR Dipyridamole/Aspirin 200 mg/25 mg modified release capsules bottle Australia - English - Department of Health (Therapeutic Goods Administration)

genpar dipyridamole/aspirin sr dipyridamole/aspirin 200 mg/25 mg modified release capsules bottle

arrotex pharmaceuticals pty ltd - aspirin, quantity: 25 mg; dipyridamole, quantity: 200 mg - capsule, modified release - excipient ingredients: hypromellose phthalate; gelatin; methacrylic acid copolymer; microcrystalline cellulose; tartaric acid; purified talc; pregelatinised maize starch; sucrose; hypromellose; triacetin; acacia; stearic acid; iron oxide red; iron oxide yellow; titanium dioxide; povidone; sodium benzoate; potable water; simethicone; cetostearyl alcohol - for the prevention of recurrent ischaemic stroke and transient ischaemic attacks.

APO-DIPYRIDAMOLE-SC TAB 25MG TABLET Canada - English - Health Canada

apo-dipyridamole-sc tab 25mg tablet

apotex inc - dipyridamole - tablet - 25mg - dipyridamole 25mg - miscellaneous vasodilatating agents

APO-DIPYRIDAMOLE-SC TAB 50MG TABLET Canada - English - Health Canada

apo-dipyridamole-sc tab 50mg tablet

apotex inc - dipyridamole - tablet - 50mg - dipyridamole 50mg - miscellaneous vasodilatating agents

APO-DIPYRIDAMOLE-SC TAB 75MG TABLET Canada - English - Health Canada

apo-dipyridamole-sc tab 75mg tablet

apotex inc - dipyridamole - tablet - 75mg - dipyridamole 75mg - miscellaneous vasodilatating agents

APO-DIPYRIDAMOLE TABLET Canada - English - Health Canada

apo-dipyridamole tablet

apotex inc - dipyridamole - tablet - 25mg - dipyridamole 25mg - miscellaneous vasodilatating agents

APO-DIPYRIDAMOLE TABLET Canada - English - Health Canada

apo-dipyridamole tablet

apotex inc - dipyridamole - tablet - 50mg - dipyridamole 50mg - miscellaneous vasodilatating agents

APO-DIPYRIDAMOLE TABLET Canada - English - Health Canada

apo-dipyridamole tablet

apotex inc - dipyridamole - tablet - 75mg - dipyridamole 75mg - miscellaneous vasodilatating agents

APO-DIPYRIDAMOLE TABLET Canada - English - Health Canada

apo-dipyridamole tablet

apotex inc - dipyridamole - tablet - 100mg - dipyridamole 100mg - miscellaneous vasodilatating agents

ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE- aspirin and extended-release dipyridamole capsule United States - English - NLM (National Library of Medicine)

aspirin and extended-release dipyridamole- aspirin and extended-release dipyridamole capsule

american health packaging - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin, usp is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis and nasal polyps. aspirin, usp may cause severe urticaria, angioedema or bronchospasm. do not use aspirin, usp in children or teenagers with viral infections because of the risk of reye syndrome. teratogenic effects, pregnancy category d. [see warnings and precautions (5.4)]. aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pr

ASPIRIN AND DIPYRIDAMOLE- aspirin and dipyridamole capsule, extended release United States - English - NLM (National Library of Medicine)

aspirin and dipyridamole- aspirin and dipyridamole capsule, extended release

teva pharmaceuticals usa, inc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. aspirin may cause severe urticaria, angioedema or bronchospasm. do not use aspirin in children or teenagers with viral infections because of the risk of reye syndrome. teratogenic effects , pregnancy category d. [see warnings and precautions (5.4) ]. aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pregnancy [se